David Berry, MD, PhD, PartnerDavid Berry is a Partner at Flagship Ventures, having joined Flagship in 2005 while completing his MD from Harvard Medical School. At Flagship, David focuses on investing in and founding early stage life science and clean technology ventures.
In 2005, he co-founded and helped launch LS9, and more recently co-founded Joule Biotechnologies where he initially served as the founding CEO. He is currently serving as founding CEO of Theracrine. In addition, David serves on the Board of Directors of Eleven Biotherapeutics and works closely with several other portfolio companies.
David's work has led to 11 peer-reviewed publications, over 20 patents and applications, as well as over twenty-five awards and honors including the prestigious Lemelson-MIT Student Prize in 2005 for invention and innovation. David was also named as the Innovator of the Year by Technology Review in its 2007 TR35 list of world’s top 35 innovators under the age of 35.
David did his undergraduate work at MIT, graduating in 2000 Phi Beta Kappa and Sigma Xi, with a degree in brain and cognitive sciences. He earned a PhD through the MIT Biological Engineering Division, where he studied the biological effects of complex sugars with advisors Professor Ram Sasisekharan and Professor Robert Langer. He was named as a member of the MIT Corporation, its Board of Trustees, in 2006, as well as a member of the Global Board for the MIT Enterprise Forum in 2010.
| 
